1 / 97

“Walking pathways” and how promoters can help to find new drugs .

“Walking pathways” and how promoters can help to find new drugs . (Practical guide to multi-omics and multi-scale data integration). Alexander Kel Biosoft.ru, Skolkovo Moscow. Wolfenbüttel. Novosibirsk. alexander.kel@genexplain.com. Trovafloxacin - antibiotic.

aviv
Télécharger la présentation

“Walking pathways” and how promoters can help to find new drugs .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. “Walking pathways” and how promoters can help to find new drugs. (Practical guide to multi-omics and multi-scale data integration) Alexander Kel Biosoft.ru, Skolkovo Moscow Wolfenbüttel Novosibirsk alexander.kel@genexplain.com

  2. Trovafloxacin - antibiotic Withdrawn from market due to risk of idiosyncratichepatotoxicity in 2001.

  3. Failure Affects National Economies:Medicines & Equitable Distribution Total: 1.3 T$ Combined treatment and productivity costs for US in 2007 Milken Institute 2008 Hensley

  4. One of the main causes of high death rate for such diseases is the unsatisfactory quality of treatment, which in the first place is brought by low efficiency and insufficient safety of today’s drugs and therapies. About 50% of prescribed medicine doesn’t have any therapeutic effect at all. Moreover, 125 thousand deaths annually (in USA) are caused by the drugs’ side effects. It becomes more and more obvious that the main cause of this crisis is the insufficient understanding of deep biological mechanisms of initiation and flowing of pathological conditions and toxicity mechanisms used in drugs.

  5. Drug discovery – the Gold Rush

  6. Drug discovery – shouldbecome a technology Disease Therapy Patient

  7. Systems medicine Systems approaches will transform the way drugs are developed … that will target multiple components of networks and pathways perturbed in diseases. They will enable medicine to become predictive, personalized, preventive and participatory Systems medicine: the future of medical genomics and healthcare Charles Auffray1*, Zhu Chen2 and Leroy Hood3 Genome Med 2009, 1:2

  8. Weshouldfind a keypathwayof a disease, selecta goodtargetandinhibit it. TRANSPATH

  9. Pathway mapping Mapping on pathways Cause of disease ?? Differentially expressed genes/proteins

  10. TNF-a 117 differentially expressed genes

  11. Can we predict TNF pathway? ? 117 differentially expressed genes

  12. Canonical TNF pathway TRANSPATH

  13. Lets do mappingthedifferentiallyexpressed genes on canonicalpathways. Not significant Not significant TNF pathwaycan not befoundbydirectmaping on canonicalpathways....

  14. Human epidermoid carcinoma A431 cells treated by epidermal growth factor (EGF) 320 differntially expressed proteins EGF

  15. Mapping differentially expressed proteins to canonical signal transduction pathways

  16. Mapping on pathwaysdoes not work(even in such a simple cases) Why ?

  17. Pathwaysarefarfrombeing fullyundersood.

  18. BIG gap of knowledge on interactions between TF and their target sites in DNA TF2 TF3 TF1 TRANSPATH

  19. ? Search for new TF binding sites with PWMs (Match algorithm) …

  20. N M k s n=k+s p=M/N

  21. Overrepresented TFs in TNF-alpha regulated promoters

  22. Master regulator

  23. Search for the reason by the analysis of the ripples

  24. Can we predict TNF pathway? ? 117 differntially expressed genes

  25. GeneXplain platform – drug target discovery pipeline

  26. TNF-alpha

  27. Human epidermoid carcinoma A431 cells treated by epidermal growth factor (EGF) ? 320 differntially expressed proteins EGF Master regulatoranalysis EGF was still not in thelist !

  28. Pathwaysarefar .....far....farfrombeingfully undersood!

  29. Combinatorial regulation „Fuzzy puzzle“

  30. AP-1 ******* TGAGTCA Human collagenase (-2013) ** ** * TGTGTAA Mouse IL-2 (-143) ** * TGTAATA Mouse IL-2 (-82) TGAgTCA Consensus:

  31. Mouse c-fos promoter (Matrix search for TF binding sites)

  32. Mouse Interleukin-2 gene promoter AP-1 COMPEL:C00050 NF-ATp . . . . . . . tgccacacaggtagactcttTTGAAAATAtgTGTAATAtgtaaaa catcgtgaca cccccatatt… … -96 -79 ST TGAGTCA One of the TF binding sites in a composite elements can be rather weak.Weak DNA-protein interactions are stabilized by protein-protein interactions. AP-1 consensus

  33. Composite Module (CM) Composite Modules (CM) (Mark Ptashne, Alexander Gann Genes and Signals, 2002)

  34. Composite Modules (CM) w Start of transcription ... ( ) ( ) k k s s ... 1 mk ... ... ... Parameters of the model to be estimated by GA ... Wecreated a geneticalgorithmto find sitecombinations

  35. Composite Modules (CM) Composite Module Score (cms) K, the number of individual PWMs in the module, (k=1,K) ... Matrix cut-off values: Relative impact values: Maximal number of best matches: mk R, the number of pairs of PWMs (r=1,R) Matrix cut-off values: Relative impact values: Maximal and minimal distances:

  36. Fitness function of the Genetic-Regression Algorithm (GRA) # promoters R – linear regression N FN – false negatives FP – false positives FN cms FP T – T-test (differencebetweenmeanvalues) N – normal likeness k – number of free parameters

  37. Composite module in promoters of cell cycle-related genes Cell cycle-related promoters Background sequences

  38. Mouse c-fos promoter

  39. Promoter structure: curret paradigm Mouse IL-4 promoter AP-1 HMG Y c-MAF AP-1 HMG Y NF-Y STAT 6 AP-1 AP-1 TATA TSS NFAT NFAT NFAT NFAT NFAT CE CE -249 -114 -180 -150 -88 -60 -28 +1

  40. Promoter is a parking place

  41. Promoter structure: reality Mouse c-fos promoter

  42. Parking in Italy

  43. ChIP-seq data: EPS-FLI1 Ewing sarcoma transcription factor – gene fusion

  44. Network plasticity „Walking pathways“

More Related